Research and Markets: Read about Pfizer's Novel Exubera In The Hotly-Contested Insulin Market for Diabetes.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c50130) has announced the addition of Diabetes Drug Discoveries: what the future holds to their offering. The diabetes market will grow significantly over the next 5 years to US$31.4 billion - who are the companies and what are the market trends and products that will drive growth? This report will tell you! A growing and valuable market There are a number of drivers in the diabetes market that are fuelling growth: Product innovation New classes of drugs such as GLP-l agonists and DPP-lV inhibitors have already been launched and the pipeline is well stocked. Combination therapies will play their part in the future as will novel drug delivery technology. Emerging markets = rapid growth Some of the fastest growing markets for diabetes are in emerging economies - India, China and Indonesia are in the top 5 for disease prevalence. The impact for both branded and generic drugs generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. is considerable. Unmet un·met adj. Not satisfied or fulfilled: unmet demands. clinical need will keep developed markets strong While the number of patients diagnosed has gone up it is estimated millions are still to be identified. In the UK alone, it is estimated that up to a million Type II sufferers are undiagnosed. Strong annual growth expected for the next five years With many new products yet to realise their full potential, and the high incidence of Type II diabetes Type II diabetes Type II diabetes is the most common form of diabetes and usually appears in middle aged adults. It is often associated with obesity and may be delayed or controlled with diet and exercise. Mentioned in: Diabetic Ketoacidosis expected in emerging markets, prospects for the sector look strong. Estimated at US$22 billion in 2007, it is forecast to grow to US$31.4 billion by 2011, with generics performing strongly as time moves on. This Report Answers Key Questions What revenue is Pfizer's novel Exubera forecast to achieve by 2011 in the hotly-contested insulin insulin, hormone secreted by the β cells of the islets of Langerhans, specific groups of cells in the pancreas. Insufficiency of insulin in the body results in diabetes. Insulin was one of the first products to be manufactured using genetic engineering. market? What are the strengths and weaknesses of Merck & Co's Januvia and Novartis' Galvus in the new DDP-IV inhibitor inhibitor /in·hib·i·tor/ (in-hib´i-tor) 1. any substance that interferes with a chemical reaction, growth, or other biologic activity. 2. sector? Which markets are showing the highest growth in terms of disease prevalence? What impact might combination therapies have in the future? How well will Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were and Merck KgaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. be able to protect future Glucophage (metformin metformin /met·for·min/ (met-for´min) an antihyperglycemic agent that potentiates the action of insulin, used in the treatment of type 2 diabetes mellitus. met·for·min n. ) revenues from generic competition? Novel Competitor Ratio Analysis Puts Products Into A Wider Market Context For a number of new and future drugs, we have provided a competitor ratio analysis, based on our assessment of the following five criteria: Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class. Each of these criteria attracts a maximum of ten points, resulting in a maximum score of 50 overall and allowing you to compare and contrast the prospects for each product This Report provides: -Unique 5 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. by product -Critical assessment and estimates, where appropriate, for 19 new and current compounds -A review of upcoming products and research strategies -Prevalence and background data Industry and investor interest in the diabetes sector has been rekindled Public awareness about the causes of Type II diabetes, an ageing population and improving diagnosis rates are fuelling market growth. Around the globe, an estimated 246 million people are living with diabetes today. By 2025, it is anticipated this number will increase to around 380 million. Each year, diabetes-related causes account for 3.8 million deaths and claim the lives of as many people as HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome . In 2007, the prevention and treatment of diabetes and its complications will cost at least US$232 billion according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. current estimates. By 2025, this is likely to increase to more than US$302.5 billion. Unmet clinical need in developed markets and a rapidly-expanding market in emerging economies will drive market growth. Innovation coming to the market Equally significant has been the introduction of new classes of drugs. The GLP-l agonists and DPP-lV inhibitors introduce a new approach while delivery technology continues to play a role with the introduction of Pfizer's Exubera - the first inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. insulin product. Understand this key market sector The diabetes market is taking an increasingly important role in industry's and investors' plans which is why we have published this critical analysis Diabetes Drug Discoveries: What the future holds. The report puts the spotlight on current and future drugs that will be used in the treatment of Type I and Type II diabetes as well as related conditions, and provides industry and investors with a complete and comprehensive overview of the market in the medium term. Companies Mentioned: -Novo Nordisk -sanofi-aventis -Pfizer -BMS/Merck -GSK -Takeda -Eli Lilly -Novartis -BMS/AstraZeneca For more information visit http://www.researchandmarkets.com/reports/c50130 Source: Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion